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1. Introduction 
Prostaglandin E, (PGE1) elevates the levels of 
intracellular adenosine 3’: 5’-cyclic monophosphate 
(cyclic AMP) in clonal lines of mouse neuroblastoma 
cells [ 1, 21 , of fibroblasts [3, 41 and of hybrid cells 
involving cell lines derived from nervous tissues or 
fibroblasts [4]. If the cell lines preserve properties 
of the nervous tissue cells from which they were 
derived, their sensitivity to PGE, should reflect a 
physiological function. PGE compounds injected in- 
to an animal disap.pear very rapidly from the circula- 
tion [5], as they are oxidized to inactive derivatives 
[6]. Consequently, the PGE to which the cells 
would respond in situ would most probably have 
to be produced in the close neighbourhood of those 
cells. Therefore, it was of interest to investigate the 
capability of a neuroblastoma, a glioma and a fibro- 
blast cell line to synthesize PGE. It has been shown 
that many actions of cyclic AMP can be mimicked 
by N6 ,02’-dibutyryl adenosine 3’:s’~cyclic mono- 
phosphate (dibutyryl cyclic AMP) [7-l 1 ] . The 
influence of this cyclic AMP analogue on the pro- 
duction of prostaglandins (PG) was measured in 
order to obtain information on the significance of 
cyclic AMP (and of neurohormones acting via cyclic 
AMP) in the regulation of PG synthesis. 
All 3 cell lines essentially produce PGE; only 
minor amounts of PGF and PGA were detected. 
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The amount of PGE synthesized per million cells 
was strongly increased in the presence of dibutyryl 
cyclic AMP. The drug markedly decreased the growth 
rates of the cell lines. 
2. Methods 
The three cell lines used were N4TG3, a 6-thio- 
guanine resistant mutant [12] of mouse neuro- 
blastoma clone N4 [ 131, C6-BU-1, a bromodeoxy- 
uridine resistant mutant [ 121 of rat glioma clone 
C 6 [14] and B82, a bromodeoxyuridine resistant 
mutant L cell line [15] . The cells were grown at 
37°C in Falcon plastic flasks (75 cm2) using Dul- 
becco’s Modified Eagle’s Medium (Gibco), supple- 
mented with 10% fetal bovine serum (Colorado 
Serum Co.), in an atmosphere of 90% air, 10% CO, 
and approximately 100% humidity. The medium 
for N4TG3 was supplemented with O.LmM6&bia-~ 
guanine (Sigma), that for C6-BU-1 and B82 with 
0.1 mM bromodeoxyuridine (Sigma). The cells were 
subcultured by brief treatment with a 0.05% solution 
of trypsin (Nutritional Biochemicals Corp.) in me- 
dium D, adjusted to 340 mOsm by the addition 
of glucose and sucrose [ 161. 
For measuring the PG production by a given cell 
line at different cell densities, two sets of flasks 
were inoculated with the same number of cells. The 
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medium in one of the sets was supplemented with 
1 mM dibutyryl cyclic AMP (Sigma). Every day, 
starting the day after inoculation, one flask of each 
set was used for cell counting (hemocytometer) and 
determination of the viability (exclusion of nigrosin), 
another for quantitation of PG. The media in all 
other flasks were renewed daily. For determination 
of PG, the supernatant growth medium was ex- 
tracted as described [17-191. The cell layer was 
washed 3 times with 8 ml of medium D, [16]. As 
the washing fluids contained negligible amounts of 
PG, they were discarded. After breaking the flasks, 
the cells were scraped off and homogenized by 
sonication in medium D,. One ml of cell homoge- 
nate was extracted with a mixture of 2 ml H,O, 
5 ml ethylacetate and 3 ml of a 3:3:1 mixture of 
ethy1acetate:isopropanol:O.l M HCl. The prosta- 
glandins A, E and F were separated by chromato- 
graphy on silicic acid and assayed by a radioim- 
munochemical method [ 191. 
3. Results 
Growth curves of the cell lines are shown in fig. I 
Dibutyryl cyclic AMP retards cell proliferation in 
all cases. The effect is most striking with the glioma 
line (fig. IB), where the final cell density reached 
in the presence of the drug is only one seventh of 
that of the untreated controls. By the first day of 
incubation with the drug, the glioma cells start dif- 
ferentiating by extending long processes (fig. 2). 
No striking morphological changes were observed 
with lines N4TG3 and B82. 
The cumulative PGE production per flask of cells 
is illustrated in fig. 3 (top). The amount of PGE 
per flask increases with time. It is only with line 
B82 (top, C) that the production per flask of PGE 
is far higher in the presence than in the absence of 
dibutyryl cyclic AMP. However, when the data are 
expressed as mount of PGE formed up to a given 
time per million cells, an entirely different picture 
A 
16 
I 
II ; 
;-/ 
,,o--_D-- D 10 
,p- 
p//n 
I’ 
/’ 
.’
1 2 3 4 5 6 7 1 2 3 4 5 
tme [days] 
6 
t Ime [days] 
0 
I lo8 
C 
7 1 2 3 4 5 
time [days] 
2-T 
Fig. 1. Proliferation of cells of 3 clonal lines in the absence (curve I) and presence (curve II) of 1 mM dibutyryl cyclic AMP: 
A) neuroblastoma line N4TG3; B) glioma line C6-BU-I ; C) fibroblast line B82. The ranges of cell viabilities were (data obtained 
in presence of dibutyryl cyclic AMP in parentheses): N4TG3, 87795% (78-96’16); CB-BU-I, 96-100% (91-100%); B82, 95-99% 
(95-9970). The total volumes of growth medium in the flask at the time the media were removed for assays of prostaglandins 
and for medium changes were 15 ml, except at the following times (rounded): N4TG3, days 5, 6, 7 (25 ml); C6-BU-1 and B82, 
day 7 (20 ml). 
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Fig. 2. Morphology of clonal glioma line C6-BU-1 grown in presence (A) and absence (B) of dibutyryl cyclic AMP. 
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Fig. 3. Top: Cumulative production of PGE in absence (curve I) and presence (curve II) of dibutyryl cyclic AMP; A) neuro- 
blastoma line N4TG3; B) glioma line C6-BU-1; C) fibroblast line B82. The flasks were replica flasks of those used for cell counts 
in fig. 1. For cell viabilities and for volumes of growth medium see fig. 1. The values for cumulative production of PGE up to a 
given time are obtained by addition of (i) the PGE content of the cells harvested at that time and (ii) the PGE contents of all the 
volumes of medium the cells had been in contact with up to that time. 
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Bottom: Cumulative production of PGE per million cells in absence (curve I) and presence (curve II) of dibutyryl Cyclic AMP. The 
values for cumulative production of PGE up to a given time were divided by the number of viable cells per flask reached at that time 
196 
Volume 36, number 2 FEBS LETTERS 
Table 1 
October 1973 
Prostaglandin production per million cells per day by three different cell lines. The data were measured at day 3 of the growth 
curves shown in fig. 1. 
Cell line DBCA* PG production (pg/106 cells/day) 
PGE 
total found in cells % of total PGE 
found in cells 
PGA 
found in 
cells 
N4TG3 _ 713 58 8 100 14 14 
+ 770 324 42 86 11 27 
C6-BU-I - 1940 148 8 53 3 24 
f 2880 167 6 195 7 41 
B82 _ 708 162 23 124 18 12 
+ 1960 1252 64 60 3 11 
* DBCA = dibutyryl cyclic AMP. 
ensues (fig. 3 bottom). The production of PGE per 
million cells by N4TG3 (bottom, A) does not in- 
crease with the cell density in absence of dibutyryl 
cyclic AMP. In the presence of the drug (curve II), 
however, the values increase with the cell density to 
3 times the control values (curve I). 
cyclic AMP. In the presence of the drug, this propor- 
tion is 6664% of the total production (table 1). 
4. Discussion 
The effect of dibutyryl cyclic AMP is even more 
impressive with the glioma line (fig. 3, bottom, B). 
In the absence of the drug, the values for PGE formed 
per million cells decrease strongly with increasing 
cell density (curve I). At low densities of C6-BU-1 
the drug inhibits production of PGE per million cells 
(curve 11). With increasing cell density the PGE forma- 
tion per million cells increases and eventually exceeds 
that of the control cultures. When the cultures be- 
come more crowded, the production per unit number 
of cells falls again but stays always several times higher 
than that of the controls (curve I). A picture quali- 
tatively similar to that for C6-BU-I is found with the 
fibroblast line B82 (fig. 3, bottom, C). 
In experiments reported previously, carcinomas, 
sarcomas and normal fibroblasts grown in matrix or- 
gan culture [20,2 1 ] as well as clonal lines derived 
from fibrosarcomas [22] were found to secrete dif- 
ferent amounts of PGE into the medium. The ex- 
periments reported here show that the 3 cell lines in- 
vestigated preferably synthesize PGE. Only minor 
amounts of PGA and PGF could be detected. In our 
experiments, PGA and PGF were only found within 
the cells. If they were excreted into the medium, the 
amounts must have been too low to be detected. 
PGA and PGF could not be detected in the me- 
dium that had been in contact with the cells for one 
day. However, low amounts of both PGA and PGF 
were found in the cells; at day three of the growth 
curves (fig. I), e.g., the average content of the three 
cell lines was between 3 and 18% of the total PGE 
production per lo6 cells per day for PGA and between 
1 and 4% for PGF (table 1). Eight to 23% of the PGE 
produced by the 3 cell lines is retained in the cells, 
when they are grown in the absence of dibutyryl 
Levine et al. [22] reported that a mouse fibroblast 
and a mouse neuroblastoma line, both different from 
those used in this study, and the wild type rat glioma 
line of which C6-BU-1 is a mutant, did not produce 
significant amounts or contained measurable intra- 
cellular levels of PG. In view of the large quantities 
of PGE the fibrosarcoma cells, investigated by these 
authors, produced, this appears to be a fair statement. 
Nevertheless, the present study shows that the three 
cell lines used synthesize PG and that the rate of syn- 
thesis can be enhanced, when dibutyryl cyclic AMP 
is added to the growth medium. As mentioned, in 
the presence of dibutyryl cyclic AMP many effects 
PGF 
%of total found in 
PGE cells 
% of total 
PGE 
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have been observed, which can also be produced by 
increasing the intracellular concentration f cyclic 
AMP [7-l 11. Therefore, our results suggest hat in 
the cells investigated cyclic AMP plays a positive 
regulatory function in the synthesis of PG. At day 5 
of the growth curve ( fig. l), N4TG3 cells enter the 
stationary phase of apparent contact inhibition of 
proliferation. This phenomenon is accompanied by 
a spurt of PC production, especially in the presence 
of dibutyryl cyclic AMP. In all cases the retardation 
of cell proliferation goes along with an increase in 
production of PGE. In the case of C6-BU-1 striking 
morphological changes also take place. An extension 
of long cell processes is also observed in other cases, 
e.g., when mouse neuroblastoma clones [IO, 11, 231 
or mouse neuroblastoma x rat glioma hybrid clones 
[24] are treated with dibutyryl cyclic AMP [ 10,23, 
241, PC [l I] or inhibitors of cyclic AMP phospho- 
diesterase [24, 251. 
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